Catalyst Patent-Cliff Exposure & CMS Drug Spending Portfolio

Catalyst (US): 3 reconciled FDA prescription therapies (42.7% 2025 to 2030 cliff risk), $412.1M 2024 CMS Part D & Medicaid spend, and 22 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure42.7%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$412.1M
2024 Medicare Part D Spend$254.2M
2024 Medicaid Spend$157.9M
California HCAI SB 17 Filings22 WAC filings (max 21.4% 2-yr change)